Ample supplies of the H1N1 vaccine have now been shipped to states, according to the Centers for Disease Control and Prevention (CDC), so it is no longer reporting on the status of state supplies or orders shipped.
Scientists from the Imperial College of London (ICL) may have uncovered a potential new way to regulate blood clotting, especially important for people with deep vein thromboses, blood clots in the legs, or hemophilia.
A December 2009 study published in the journal Science has shown the potential of a new type of treatment for patients with the hepatitis C virus (HCV), an alternative therapy that affects the virus's capacity to replicate.
Last month Octapharma USA announced that the U.S. Food and Drug Administration (FDA) had approved Wilate®, an injectable human-derived von Willebrand factor (VWF)/factor VIII (FVIII) concentrate for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease (VWD).
Researchers from the University of Colorado (UC) tested the relative effects of low- and high-impact athletic activity on the joints of school-aged children with severe hemophilia A or B on a prophylaxis (preventive) treatment regimen.
In a December 2009 study, researchers in China evaluated the efficacy and safety of pegylated interferon (PEG-IFN) alpha-2a monotherapy in Chinese hemophilia patients co-infected with the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV).